Edwards Lifesciences (NYSE:EW) Price Target Raised to $101.00 at Royal Bank of Canada

Edwards Lifesciences (NYSE:EW) had its price objective lifted by Royal Bank of Canada from $95.00 to $101.00 in a research note released on Monday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the medical research company’s stock.

EW has been the subject of a number of other research reports. Mizuho lifted their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a buy rating in a research note on Thursday, April 11th. Truist Financial lifted their price target on shares of Edwards Lifesciences from $78.00 to $84.00 and gave the stock a buy rating in a research note on Friday, December 22nd. Wells Fargo & Company upgraded shares of Edwards Lifesciences from an equal weight rating to an overweight rating and set a $94.00 price target for the company in a research note on Friday, February 2nd. Evercore ISI lifted their price target on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the stock an in-line rating in a research note on Thursday, April 4th. Finally, Stifel Nicolaus lifted their price target on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the stock a hold rating in a research note on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of Moderate Buy and a consensus target price of $91.73.

Edwards Lifesciences Trading Down 1.2 %

NYSE EW opened at $89.20 on Monday. The firm has a 50 day simple moving average of $90.07 and a 200-day simple moving average of $77.92. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. Edwards Lifesciences has a one year low of $60.57 and a one year high of $96.12. The firm has a market cap of $53.69 billion, a price-to-earnings ratio of 38.78, a PEG ratio of 4.47 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same quarter last year, the firm posted $0.64 earnings per share. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. Equities research analysts anticipate that Edwards Lifesciences will post 2.76 EPS for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 in the last ninety days. 1.29% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently made changes to their positions in EW. Nordea Investment Management AB boosted its position in shares of Edwards Lifesciences by 1,224.1% in the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock worth $123,261,000 after buying an additional 1,488,791 shares in the last quarter. Arlington Trust Co LLC boosted its position in shares of Edwards Lifesciences by 5,092.4% in the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock worth $938,000 after buying an additional 12,069 shares in the last quarter. Versor Investments LP boosted its position in shares of Edwards Lifesciences by 83.3% in the 3rd quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock worth $311,000 after buying an additional 2,043 shares in the last quarter. Gateway Investment Advisers LLC boosted its position in shares of Edwards Lifesciences by 12.2% in the 4th quarter. Gateway Investment Advisers LLC now owns 253,337 shares of the medical research company’s stock worth $19,317,000 after buying an additional 27,519 shares in the last quarter. Finally, US Bancorp DE boosted its position in shares of Edwards Lifesciences by 0.6% in the 3rd quarter. US Bancorp DE now owns 850,257 shares of the medical research company’s stock worth $58,906,000 after buying an additional 5,409 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.